Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT04697459
Other study ID # 2020-09-14
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date December 13, 2020
Est. completion date September 30, 2023

Study information

Verified date November 2023
Source University of Avignon
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The main objective is to assess the effects of chronic intradialytic physical exercise on myocardial remodelling and regional function.


Description:

Background: Hemodialysis patients have a mortality rate 50 times higher than in the general population, and the cause remains cardiovascular in more than half of the cases. A deleterious morphological and functional cardiac remodelling is well established in these patients, the causes of which are both the presence of factors specific to renal disease (hemodynamic and non-hemodynamic) and co-morbidities (diabetes, hypertension, etc. .) but also to the hemodialysis (HD) procedure itself, due to the sudden hemodynamic changes it imposes, leading to repeated episodes of intradialytic hypotension (HID) and myocardial stunning. The latter are now documented as direct contributors to the increased mortality observed in HD patients compared to the general population. The introduction of intradialytic physical exercise in the therapeutic program of HD patient is now recommended and practised routinely in many countries, in Scandinavia in particular. Several meta-analyses have clearly established its safety. The beneficial role of chronic intradialytic exercise in improving dialysis efficiency, mental health and quality of life, as well as the inflammatory status of HD patients is also clearly demonstrated. Chronic intradialytic exercise is also associated with improvements in overall fitness level, a parameter closely linked to cardiovascular mortality. Applied acutely during dialysis, it could play a cardioprotective role (e.g; limiting myocardial stunning), allowing haemodynamic and cardiac functional stabilization during HD. However, to our knowledge, no study to date has investigated the long-term effects of intradialytic exercise on remodelling and overall and regional heart function. Aims: The main objective is to assess the effects of chronic intradialytic physical exercise on myocardial remodelling and regional function. The secondary objectives are to evaluate the effect of acute intradialytic exercise on myocardial stunning as well as the effect of chronic physical exercise on macro and microcirculatory vascular function, inflammation, physical fitness and health-related quality of life.


Recruitment information / eligibility

Status Completed
Enrollment 61
Est. completion date September 30, 2023
Est. primary completion date May 14, 2023
Accepts healthy volunteers No
Gender All
Age group 20 Years to 79 Years
Eligibility Inclusion Criteria: - No medical contraindication to physical activity - Life expectancy greater than 6 months - Patients on haemodialysis for more than 3 months Exclusion Criteria: - Pregnancy - Valvular heart disease, - Unstable coronary artery disease - Arteriopathy obliterating of the lower limbs stage III and IV - Musculoskeletal problems - Severe respiratory disease - BMI> 35 - Pacemaker, cardiac stimulation and automatic implantable defibrillator - Heart transplant - Uncontrolled arterial hypertension - Ejection fraction <45%

Study Design


Related Conditions & MeSH terms


Intervention

Other:
chronic phase
1h of intradialytic execise, starting 30 min after hemodialysis beginning : 30 min of low-intensity (Borg Scale 11-14) aerobic exercise + 30 min of resistance training, frequency : 3 times a week for 16 weeks.
acute phase
30 min of low-intensity (Borg Scale 11-14) aerobic exercise, starting 30 min after hemodialysis beginning

Locations

Country Name City State
France ATIR Avignon Vaucluse
France Centre Hemodialyse AIDER sante Nîmes Gard

Sponsors (1)

Lead Sponsor Collaborator
University of Avignon

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Changes in myocardial longitudinal deformations Myocardial longitudinal linear deformations (in percent) will be assessed by high-resolution echocardiography in deformation imaging mode. Acute phase : just before and 90 and 210 minutes within standard dialysis or dialysis including acute exercise.
Primary Changes in myocardial longitudinal deformations Myocardial longitudinal linear deformations (in percent) will be assessed by high-resolution echocardiography in deformation imaging mode. Chronic phase : before (week 0) and after (week 17) an exercise training program of 16 weeks; each time in the same conditions as in acute phase (e.g. just before and 90 and 210 minutes within standard dialysis or dialysis including acute exercise).
Primary Changes in myocardial circumferential deformations Myocardial circumferential linear deformations (in percent) will be assessed by high-resolution echocardiography in deformation imaging mode. Acute phase : just before and 90 and 210 minutes within standard dialysis or dialysis including acute exercise.
Primary Changes in myocardial circumferential deformations Myocardial circumferential linear deformations (in percent) will be assessed by high-resolution echocardiography in deformation imaging mode. Chronic phase : before (week 0) and after (week 17) an exercise training program of 16 weeks; each time in the same conditions as in acute phase (e.g. just before and 90 and 210 minutes within standard dialysis or dialysis including acute exercise).
Primary Changes in left ventricular torsion Left ventricular torsion (in degree) will be assessed by high-resolution echocardiography in deformation imaging mode. Acute phase : just before and 90 and 210 minutes within standard dialysis or dialysis including acute exercise.
Primary Changes in left ventricular torsion Left ventricular torsion (in degree) will be assessed by high-resolution echocardiography in deformation imaging mode. Chronic phase : before (week 0) and after (week 17) an exercise training program of 16 weeks; each time in the same conditions as in acute phase (e.g. just before and 90 and 210 minutes within standard dialysis or dialysis including acute exercise).
Secondary Changes in arterial rigidity Measurement of pulse wave velocity (m/s) by photo-plethysmography at rest before dialysis. before (week 0) and after (week 17) an exercise training program of 16 weeks
Secondary Changes in Physical fitness The six-minute walking test (meters); maximal isometric force (newtons) during a knee-extension test and handgrip test using a dynamometer. before (week 0) and after (week 17) an exercise training program of 16 weeks
Secondary Health-related Quality of life The 36-Item Short Form Health Survey questionnaire. The SF-36 consists of eight scaled scores, which are the weighted sums of the questions in their section. Each scale is directly transformed into a 0-100 scale on the assumption that each question carries equal weight. The lower the score the more disability. before (week 0) and after (week 17) an exercise training program of 16 weeks
Secondary Changes in carotid intimal-media wall thickness The intimal plus media wall thickness (mm) of the right carotid artery will be measured using high-resolution echography. before (week 0) and after (week 17) an exercise training program of 16 weeks
See also
  Status Clinical Trial Phase
Recruiting NCT02565459 - MSC and Kidney Transplant Tolerance (Phase A) Phase 1
Recruiting NCT02356419 - rESP Medication With a Single Intravenous Administration and Dose Escalation to Explore the Tolerability ,Safety and Pharmacokinetic Characteristics Phase 1
Recruiting NCT01876017 - Safety and Efficacy of BMMNC in Patients With Chronic Renal Failure Phase 1/Phase 2
Withdrawn NCT03019159 - Assessment of a Follow-up With Tele-consulting for Patients With Renal Failure Under Peritoneal Dialysis N/A
Completed NCT02047006 - Dose-finding of Rivaroxaban in Hemodialysis Phase 4
Completed NCT01617824 - Rapid Effects Linagliptin on Monocyte Polarization and Endothelial Progenitor Cells in Type 2 Diabetes Phase 4
Completed NCT00828776 - Pharmacodynamics and Non-Clinical Inferiority of Heparin Sodium (Cristália) Compared With the Product Liquemine (Roche) in Chronic Renal Failure Phase 2/Phase 3
Completed NCT00597753 - Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis Phase 3
Terminated NCT00372489 - Extension Study to Evaluate Safety and Tolerability of Peginesatide for Long-Term Treatment of Anemia in Participants With CKD Phase 2
Completed NCT00379899 - ADVANCE: Study to Evaluate Cinacalcet Plus Low Dose Vitamin D on Vascular Calcification in Subjects With Chronic Kidney Disease Receiving Hemodialysis Phase 4
Completed NCT00228436 - Safety, PD & PK of Multiple Doses of Peginesatide for Anemia in Chronic Kidney Disease Patients Phase 2
Completed NCT03772171 - Estimate for Dietary Intakes and Hemodialysis Patients
Recruiting NCT02586402 - Safety & Efficacy of Pegolsihematide for Treatment of Anemia in Participants on Dialysis Phase 2
Completed NCT01879618 - Use Of Fragmin In Hemodialysis Phase 3
Not yet recruiting NCT01346215 - Study of Clinical Non-inferiority of Actparin® (Laboratorio Bergamo) Compared to Heparin Sodium (APP Pharmaceuticals), in Patients With Chronic Renal Failure Phase 3
Completed NCT01220843 - FGF23 Reduction : Efficacy of a New Phosphate Binder in CHronic Kidney Disease Phase 3
Completed NCT01111630 - Study of Erythropoietin (EPO) Administration Schedule Phase 4
Completed NCT00742716 - Safety Study of CTA018 Injection to Treat Stage 5 Chronic Kidney Disease Phase 2
Completed NCT00598273 - Safety & Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis Phase 3
Completed NCT00597584 - Safety & Efficacy of Peginesatide for Maintenance Treatment of Anemia in Participants With Chronic Kidney Disease on Hemodialysis Phase 3